Cannabidiol (prescription)

Prescription cannabidiol (CBD), FDA-approved for seizures in Lennox-Gastaut syndrome, Dravet syndrome and tuberous sclerosis complex, ages 1 and older.

psilodex.org/m/cannabidiol-rx · data v2026.10.04

Clinical contraindication: None listed; No clinical contraindication identified.
Psilocybin evidence: Mechanism only
Half-life: 56–61 h; Approximate, in adults. Source under Interaction below.

Named in state rules?

Not namedColorado

Not namedOregon

PendingNew Mexico

Cite asPsilodex, “Cannabidiol (prescription)”, v2026.10.04. psilodex.org/m/cannabidiol-rx

Clinical data and state rules are separate facts. Both are shown; neither is a decision.

What it is used for

FDA status

FDA-approved

Availability

Sources [1]

FDA-approved for

Seizures associated with Lennox-Gastaut syndrome
Seizures associated with Dravet syndrome
Seizures associated with tuberous sclerosis complex

Sources [1]

01 Interaction with psilocybin

In theory it may raise psilocin levels; it causes sleepiness, and its label lists suicidal thoughts and liver enzyme rises.

Detail No clinical interaction data with psilocybin. The label states cannabidiol inhibits UGT1A9 and exposure to UGT1A9 substrates may increase, so psilocin levels could rise in theory. Label warnings: somnolence and sedation, suicidal thoughts or behavior, transaminase elevations, and higher seizure risk with abrupt withdrawal. The label also describes postmarketing cases of cholestatic or mixed liver injury. Sources [1]

Human data with psilocybin: None known: no published human data with psilocybin
Half-life: 56–61 h (FDA label, checked 2026-10-03) Twice-daily dosing for 7 days in healthy subjects.

Evidence types on this record

Mechanism onlyMechanism only (theoretical)

02 Pharmacology relevant to psilocybin

5 listed · counted on reports

Sedating or CNS depressant: Slows the central nervous system: drowsiness, slower reactions and impaired coordination, and slowed breathing at high doses. Effects add with other sedating substances. Sources [1]
Withdrawal or rebound if stopped abruptly: Stopping suddenly can cause withdrawal or a rebound of symptoms. Sources [1]
Liver injury: The label or source warns of liver injury, from raised liver enzymes to liver failure. Liver disease also affects how the body clears psilocin. Sources [1]
Psychiatric reactions: The label or source warns of psychiatric effects such as psychosis, mania, hallucinations, suicidal thoughts or severe mood or behavior changes. Psilocybin can also bring up strong emotions, so these warnings are relevant to screening. Sources [1]
UGT inhibition (theoretical effect on psilocin levels): Inhibits UGT enzymes (glucuronidation), the main route by which the body clears psilocin. In theory this could raise psilocin levels or lengthen the effect. Sources [1]

03 State rules

Plain-language summary · official text governs

CO4 CCR 755-1

Not named

No provision names this medication or its class.

Colorado · checked 2026-09-30

OROAR 333-333

Not named

No provision names this medication or its class.

Oregon · checked 2026-09-30

NM7.35.3 NMAC (proposed)

Pending

New Mexico's clinical rules (proposed 7.35.3 NMAC) are not final. No provision naming this medication has been found.

New Mexico · checked 2026-10-02

04 Conditions to ask about

Screening items in state rules

This medication is usually taken for a condition. State rules screen for some conditions directly, so the medication is a prompt to ask about them. Confirm with the participant; never assume a condition from the medication.

Seizure disorder (Lennox-Gastaut syndrome, Dravet syndrome or tuberous sclerosis complex)

05 Sources

EPIDIOLEX (cannabidiol) oral solution (Jazz) · FDA label (DailyMed) — revised 2026-05-29 | 9.1: not a controlled substance | cns_depressant: "EPIDIOLEX can cause somnolence and sedation." | psychiatric_reactions: "Antiepileptic drugs (AEDs), including EPIDIOLEX, increase the risk of suicidal thoughts or behavior in patients taking these drugs for any indication." | discontinuation_risk: "risk of increased seizure frequency and status epilepticus" | ugt_inhibition: "Cannabidiol is an inhibitor of UGT1A9" | interaction: "Increases in exposure of UGT1A9 substrates may be observed when concomitantly used with EPIDIOLEX." | about: "EPIDIOLEX can cause transaminase elevations." | half_life: "The half-life of cannabidiol in plasma was 56 to 61 hours after twice-daily dosing for 7 days in healthy subjects." | liver_injury: Warnings and Precautions 5.1 Hepatic Injury "EPIDIOLEX can cause dose-related elevations of liver transaminases (alanine aminotransferase [ALT] and/or aspartate aminotransferase [AST])."

Record history

v2026.10.02First published.
2026-10-03Last reviewed against its sources.

Report an error in this record →